Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
9 i* M2 M9 c$ J4 Z$ V6 j% }' B4 I+ D4 ]! k
: P! v6 b( W8 {6 b
Sub-category:# R: k( r+ J# t; c
Molecular Targets
& I: h; L3 h# n) c# L7 j6 K2 b1 K; b( D6 R( D$ I \' a
! D; R0 P/ _3 H: `7 cCategory:% Y0 X$ F- {6 V8 ^" J" |
Tumor Biology 5 `0 A o c- n8 Z+ i9 s
* O+ ]$ ^( l: T; u6 h
: `2 X; @. M. m! k
Meeting:% J# Y. R9 R/ |3 \) h* Z T
2011 ASCO Annual Meeting
! I/ O; r: K& Z y. Q- ~. u. V+ v+ V' h3 t3 z0 x; \
0 O3 f4 B$ t' ~5 PSession Type and Session Title:
* y* S6 s3 K7 @0 a( kPoster Discussion Session, Tumor Biology 9 O% A" k' p! U6 K& _8 d, ~
! `! ?5 }5 x4 ]% w) A9 o. G
) T c" p B+ V; Q( j3 B
Abstract No:% |* G) b6 e R2 l" Y( \$ [3 N; Y
10517
. P. Q& i$ v0 w5 h @" ~/ m2 h. P
! z: ], b4 M9 n: z! H! e: g# t2 C1 o; R! r5 L7 J# W0 m
Citation:& n4 i2 \* p4 e( U
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. K6 M: Y" j; P) U$ A% @! h4 @
$ T6 v5 g! m- @( [
Author(s):
! `8 [' O. ]* E ?1 f8 X2 D. u0 ]+ AJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China / ^* k: F) S5 k3 W3 c
7 t3 [/ o3 g- o
# h3 L" h' w, _5 c# z
9 ^0 C5 u' _8 t% { x" PAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
* t, [1 l3 {( @8 W% e9 _* m. c7 b
* b0 p. H4 ?& ~# }6 t; a$ XAbstract Disclosures4 V/ K; X, m3 ^2 X s) c7 r
8 e& E2 i H" N; L
Abstract:
# W+ k2 `5 k+ ?$ l4 E! |) G% R4 i8 ]: J t$ H! y, |. O
2 o* R: N6 k6 M8 z( H1 X/ x% h5 y
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.' C! V! H& b: W6 O& ` v' K' X
0 @' w" p& n$ u0 } N" e
1 Q( {9 A; D/ o) X |